Influenza virus vaccine intranasal - Acambis/Evans Vaccines

Drug Profile

Influenza virus vaccine intranasal - Acambis/Evans Vaccines

Latest Information Update: 11 Dec 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acambis; Evans Vaccines
  • Developer Acambis; Evans Vaccines; West Pharmaceutical Services Drug Delivery and Clinical Research Centre
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 11 Dec 2000 Peptide Therapeutics is now called Acambis
  • 24 Oct 2000 PowderJect Pharmaceuticals has acquired Medeva's vaccines business from Celltech and now calls it Evans Vaccines
  • 22 Jul 1998 Discontinued-I for Influenza virus infections in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top